PapersPMID:21942436
Administration of dehydroepiandrosterone (DHEA) enhances visual-spatial performance in postmenopausal women.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- crossover · 4 weeks
- Dose studied, every finding
- 50 mg oral DHEA daily (capsules compounded by Belmar Pharmaceutical) for one 4-week period
- Population, every finding
- postmenopausal women aged 55-80 not using hormone replacement therapy, DHEA versus lactose placebo crossover with a 1-week washout
No finding here moved its endpoint.
What did not
How to read these marks →“In contrast, cortisol, another adrenal product, was not affected by DHEA administration.”
“A paired samples t test revealed that the Beck Depression Inventory (BDI) scores were not significantly different (p >.5) between the DHEA condition (M= 2.08, SD = 2.04) and the placebo condition (M = 2.63, SD = 2.93).”
Study record
- Design
- crossover trial
- Species
- human
- Population
- postmenopausal women aged 55-80 not using hormone replacement therapy
- Participants
- 24
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 43